Companies / Aprea Therapeutics, Inc. / Activity
Activity — Aprea Therapeutics, Inc.
10 moves.
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Gilad Oren CEO | Buy | Common Stock | $25.0K | +28K +8.13% | 373,720 2.97% of shares | low |
| Jan 30, 2026 | Hamill John P. Executive | Buy | Common Stock | $5.1K | +6K +20.55% | 33,433 0.27% of shares | low |
| Jun 16, 2026 | Henneman John B III Director | Grant | Common Stock | $0 | +3K +30.65% | 13,364 0.11% of shares | low |
| Mar 12, 2026 | Gilad Oren CEO | Grant | Common Stock | $0 | +20K +5.40% | 393,895 3.13% of shares | low |
| Mar 12, 2026 | Hamill John P. Executive | Grant | Common Stock | $0 | +10K +30.19% | 43,528 0.35% of shares | low |
| Jun 16, 2026 | Henneman John B III Director | Grant | Stock Options (Right to Buy) | — | +13K | 12,555 0.10% of shares | low |
| Mar 12, 2026 | Gilad Oren CEO | Grant | Stock Options (Right to Buy) | — | +81K | 80,700 0.64% of shares | low |
| Mar 12, 2026 | Hamill John P. Executive | Grant | Stock Options (Right to Buy) | — | +40K | 40,380 0.32% of shares | low |
| Jan 30, 2026 | Gilad Oren CEO | Buy | Common Warrant | — | +28K | 28,100 0.22% of shares | low |
| Jan 30, 2026 | Hamill John P. Executive | Buy | Common Warrant | — | +6K | 5,700 0.05% of shares | low |